Inito has raised $29 million in a Series B funding round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures, bringing the startup’s total equity funding to $45 million.
The fresh capital will support the company’s expansion beyond fertility testing into a broader at-home hormone and health diagnostics platform powered by AI-engineered antibodies.
Founded in 2021, Inito initially launched an at-home fertility monitor that enables quantitative hormone diagnostics outside of clinical settings. The device measures key biomarkers including FSH, estrogen, LH and PdG, and Inito’s AI models interpret these results to reveal hormone patterns. According to company data, the system has analysed more than 30 million hormone data points globally and has supported tens of thousands of pregnancies at a scale comparable to the entire US IVF industry.
The new funding will accelerate Inito’s transition from a fertility-focused product to a platform that can deliver a wider range of at-home health tests.
Central to this expansion is the use of AI-engineered antibodies, developed through computational protein design and machine learning. This approach aims to overcome limitations of traditional animal-derived antibodies — which are slower to produce and less consistent — by creating synthetic antibodies with greater sensitivity and reliability, enabling accurate point-of-care tests for more biomarkers.
Inito’s leadership team plans to leverage the capital to advance development of new diagnostic tests, broaden the company’s product portfolio, and scale global distribution. The company already holds more than 20 patents and operates with a growing international team across Bengaluru, Dubai and London as it pushes toward making clinical-grade health insights accessible at home.
